Enterprise Value

1.559B

Cash

331.1M

Avg Qtr Burn

-49.12M

Short % of Float

13.63%

Insider Ownership

3.76%

Institutional Own.

96.69%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RP-L102 Details
Rare diseases, Blood disorder

BLA

Submission

RP-L201 Details
Immunodeficiency

BLA

Submission

RP-L301 Details
Pyruvate Kinase Deficiency

Phase 2

Initiation

RP-A501 Details
Immunodeficiency

Phase 2

Initiation

RP-L401 Details
Infantile Malignant Osteopetrosis (IMO)

Phase 1

Update

RP-A601 Details
Heart disease

Phase 1

Initiation